Sanofi says Zaltrap cancer drug study positive
PARIS (Reuters) - French drugmaker Sanofi said on Monday that the results of a late-stage study of its Zaltrap drug showed a "statistically significant improvement in overall survival" in patients with colon cancer.
The detailed results of the Phase III study of the drug used in conjunction with chemotherapy were published in the October edition of the Journal of Clinical Oncology, Sanofi said in a statement.
Zaltrap, also known as aflibercept, is a so-called anti-angiogenic agent, designed to starve tumors of blood.
- French warplanes search Mali desert for crashed Air Algerie plane |
- At least 15 killed by shelling of Gaza school; toll exceeds 760 |
- Exclusive: Ukraine rebel commander acknowledges fighters had BUK missile
- U.S. House panel votes to authorize lawsuit against Obama
- Lawyers call for outside probe of 'bungled' Arizona execution |
Robert Blendon of the Harvard School of Public Health says the Affordable Care Act's unpopularity in 12 key states will keep it a central issue in the 2014 elections. Video